Lixisenatide for type 2 diabetes mellitus

Bibliography

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;20(1):4-14
   Web of Science ®Google Scholar
• Goke B. Islet cell function: alpha and beta cells–partners towards normoglycaemia. Int J Clin Pract 2008;62(Suppl s159):2-7
   PubMed Web of Science ®Google Scholar
• Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes 2010;59(5):1117-25
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Barnett AH, Betteridge DJ, Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010;53(7):1258-69
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32(1):193-203
   PubMed Web of Science ®Google Scholar
• Riddle MC. Therapy: what evidence should guide the use of thiazolidinediones? Nat Rev Endocrinol 2010;6(11):600-2
   PubMed Web of Science ®Google Scholar
• Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009;5(5):262-9
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87(4):1409-39
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002;87(3):1239-46
   PubMed Web of Science ®Google Scholar
• Deacon CF, Nauck MA, Toft-Nielsen M, Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995;44(9):1126-31
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80(3):952-7
   PubMed Web of Science ®Google Scholar
• Christensen M, Knop FK. Once-weekly GLP-1 agonists: how do they differ from exenatide and liraglutide? Curr Diab Rep 2010;10(2):124-32
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Public Assessment Reports – Byetta – Scientific Discussion [Internet]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human_med_000682.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Cited 5 November 2010]
   Google Scholar
• European Medicines Agency. European Public Assessment Reports – Victoza [Internet]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001026/human_med_001137.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125 [Cited 9 November 2010]
   Google Scholar
• Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)–preclinical and clinical results. Best Pract Res Clin Endocrinol Metab 2009;23(4):463-77
   PubMed Web of Science ®Google Scholar
• Thorkildsen C, Neve S, Larsen BD, Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice. J Pharmacol Exp Ther 2003;307(2):490-6
   PubMed Web of Science ®Google Scholar
• Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept 2010;164(2-3):58-64
   PubMed Web of Science ®Google Scholar
• Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46(1):3-19
   PubMed Web of Science ®Google Scholar
• Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues. Horm Metab Res 2008;40(3):172-80
   PubMed Web of Science ®Google Scholar
• Werner U, Vandewalle B, Kerr Conte J, U. The GLP-1 receptor agonist AVE0010 improves GSIS, prevents lipotoxicity-induced insulin depletion and preserves beta-cell function in human pancreatic islets [abstract 11-OR]. Diabetes 2008;57(Suppl 1):A3-4
   PubMed Web of Science ®Google Scholar
• Haschke G, Haag-Diergarten S, Werner U, The GLP-1 receptor agonist AVE0010 preserves beta cell function and insulin secretion after a 6 week treatment in male obese Zucker diabetic fatty rats – an isolated perfused pancreas study. Diabetologia 2006;49(Suppl 1):400-1
   Google Scholar
• Moore MC, Werner U, Smith MS, Effect of the glucagon like peptide-1 receptor agonist AVE0010 on postprandial hepatic glucose metabolism in the conscious dog. Diabetologia 2007;50(Suppl 1):S242
   Google Scholar
• Werner U, Gerlach M, Hofmann M, Herling AW. The GLP-1 receptor agonist AVE0010 abolishes OGTT-induced blood glucose excursion in healthy, normoglycemic dog without risk of hypoglycaemia [abstract]. Diabetes 2007;56(Suppl 1):A129-30
   Google Scholar
• Distiller L, Ruus PE. Pharmacokinetics and pharmacodynamics of GLP-1 agonist AVE0010 in type 2 diabetes patients [abstract 520-P]. 68th Ann Meet Am Diabetes Assoc; 08 June 2008
   Google Scholar
• Liu Y, Ruus P. Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patient with renal impairment [abstract 557-P]. 69 Ann Meet Am Diabetes Assoc
   Google Scholar
• Becker RHA, Ruus P, Liu Y-H, Kapitza C. Restoration of insulin release with lixisenatide in patients with type 2 diabetes [poster 850]. EASD 46th Annual Meeting; 20 – 24 September; Stockholm, Sweden
   Google Scholar
• Liu Y, Ruus P. Effect of the GLP-1 agonist AVE0010 on absorption of concomitant oral drugs [abstract 495-P]. 69 Ann Meet Am Diabetes Assoc; 2009
   Google Scholar
• Rosenstock J, Ratner R. Post-meal effects of AVE0010, a once-daily GLP-1 receptor agonist, in type 2 diabetes inadequately controlled on metformin [abstract 564-P]. 69 Ann Meet Am Diabetes Assoc
   Google Scholar
• Gerich JE, Fonseca VA. Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly improves glycaemic control in type 2 diabetic patients. Poster 830 at EASD 46th Annual Meeting; 20 – 24 September 2010; Stockholm, Sweden
   Google Scholar
• Ratner R, Rosenstock J, Boka G. A dose-finding study of the new GLP-1 agonist AVE0010 in type 2 diabetes insufficiently controlled with metformin [abstract 433-P]. 68th Ann Meet Am Diabetes Assoc; 8 June 2008
   Google Scholar
• Ratner RE, Rosenstock J, Boka G. Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabet Med 2010;27(9):1024-32
   PubMed Web of Science ®Google Scholar
• Feinglos M, Dailey G, Cefalu W, Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract 2005;68(2):167-75
   PubMed Web of Science ®Google Scholar
• Ward WK, Beard JC, Porte D. Clinical aspects of islet B-cell function in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1986;2(3-4):297-313
   PubMedGoogle Scholar
• Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28(3):253-83
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53
   PubMed Web of Science ®Google Scholar
• Butler AE, Janson J, Bonner-Weir S, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003;52(1):102-10
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372(9645):1240-50
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374(9683):39-47
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Toft-Nielsen MB, Krarup T, Evaluation of beta-cell secretory capacity using glucagon-like peptide 1. Diabetes Care 2000;23(6):807-12
   PubMed Web of Science ®Google Scholar
• Goke R, Fehmann HC, Linn T, Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993;268(26):19650-5
   PubMed Web of Science ®Google Scholar
• van Eyll B, Lankat-Buttgereit B, Bode HP, Signal transduction of the GLP-1-receptor cloned from a human insulinoma. FEBS Lett 1994;348(1):7-13
   PubMed Web of Science ®Google Scholar
• Astrup A, Rossner S, Van Gaal L, Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374(9701):1606-16
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Klaff LJ, Schwartz S, Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33(6):1173-5
   PubMed Web of Science ®Google Scholar
• Kielgast U, Holst JJ, Madsbad S. Treatment of type 1 diabetic patients with residual beta cell function with the once-daily glucagon-like peptide-1 analogue liraglutide. 46th EASD Annual Meeting; 21 September 2010; Stockholm, Sweden
   Google Scholar
• Nikolaidis LA, Mankad S, Sokos GG, Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109(8):962-5
   PubMed Web of Science ®Google Scholar
• Nystrom T, Gutniak MK, Zhang Q, Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004;287(6):E1209-15
   PubMed Web of Science ®Google Scholar
• Gill A, Hoogwerf BJ, Burger J, Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373(9662):473-81
   PubMed Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30(8):1448-60
   PubMed Web of Science ®Google Scholar